Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive...

Area of Science:

• Urology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Prostate cancer diagnosis and risk stratification are critical for patient management.
• Current diagnostic methods can be invasive and may have limitations.
• There is a need for accurate, noninvasive biomarkers for prostate cancer.

Purpose of the Study:

• To report the development and performance of a novel platform interrogating urinary exosomal small noncoding RNAs (sncRNAs).
• To introduce the Sentinel™ PCa Test for classifying prostate cancer presence.
• To present the miR Sentinel CS and HG Tests for stratifying prostate cancer risk.

Main Methods:

• Extraction of sncRNAs from urinary exosomes of 235 participants.
• Interrogation using miR 4.0 microarrays and proprietary algorithms.
• Validation on a case-control sample of 1,436 subjects.

Main Results:

• The Sentinel PCa Test achieved 94% sensitivity and 92% specificity.
• The Sentinel CS Test showed 93% sensitivity and 90% specificity for Grade Group 2+ cancer.
• The Sentinel HG Test demonstrated 94% sensitivity and 96% specificity for Grade Group 3+ cancer.

Conclusions:

• Urinary exosomal sncRNAs can be effectively interrogated for prostate cancer diagnosis.
• The Sentinel tests offer high sensitivity and specificity for noninvasive prostate cancer detection and classification.
• This platform provides a precise, noninvasive tool for managing prostate cancer.